GenIP PLC - Operational Update, Placing and TVR
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION (EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE
GenIP Plc
("GenIP" or the "Company")
Operational Update, Placing to Accelerate Growth and Total Voting Rights
GenIP Plc is pleased to announce that it has raised
Operational Update
GenIP has moved from an early-stage company traded on AIM to a revenue generating partner for universities, corporates and investors in innovation triage and commercialisation.
Key achievements:
· Expanded the product suite beyond single technology evaluations to portfolio and macro level tools for budget holders across universities, corporates and grant institutions.
· Established recurring client relationships with universities across six continents - validating the commercial value of GenIP's products.
· Secured new contracts in new territories -
· Formed strategic LATAM partnerships providing direct access to more than 500 innovation focused institutions -
Strategic Investment
This Placing is a strategic investment focused on capturing market opportunities and driving automation into new products that will deliver enhanced gross margins.
Together, this will establish a technical foundation for future growth and scale.
Use of Proceeds: High-Margin Automation & Scalability
The net proceeds of the Placing will be used in two ways:
For Platform automation and integration leading to margin growth (Primary Focus): (67%)
● Embed the new high value products (Invention Validator, Invention Prioritizer, and Competitive Intelligence Reports) into the core Invention Evaluator platform.
● Manual processes will be reduced through automation and embedding, leading to higher gross margins and scalability.
● These products are already commercially adopted in
For Targeted Commercial Conversion in
● Technology transfer in
● GenIP has already secured significant contracts in
"This investment enables the technical integration of our new, high-value products into a single, automated platform. This directly supports margin growth and establishes the essential foundation for scalable expansion."
Placing
The Company has raised
Broker Warrants
As consideration for its services in connection with the Placing, the Company will issue the Broker with warrants over such number of Ordinary Shares as is equal to 5 per cent. of the Placing Shares (each a "Broker Warrant"). Each Broker Warrant will be exercisable at 10p up until three years from the date of Admission.
Concert Party interest
The Concert Party (as defined in the Admission Document published on
Application for Admission
Application has been made for the Placing Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will take place and that trading will commence on AIM at
Total Voting Rights
Following Admission of the Placing Shares, the enlarged issued share capital of the Company will comprise 20,517,461 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Consequently, 20,517,461 is the figure which may be used by shareholders from Admission as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
ENDS
For further information regarding GenIP, please visit www.genip.ai, or contact:
|
GenIP Plc |
|
Via Redchurch Communications |
|
|
|
|
|
Beaumont Cornish Limited (Nominated Adviser)
|
|
Tel: +44 (0) 20 7628 3396
|
|
AlbR Capital Limited (Broker) |
|
Tel: +44 (0)20 7399 9427
|
|
Redchurch Communications (Financial PR)
|
|
|
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Notes to Editors
About GenIP
GenIP is a next-generation company at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
|
Service |
Description |
Value Proposition |
|
Invention Intelligence Product Suite |
AI-powered market intelligence reports assessing the commercial potential of emerging technologies.
Invention Evaluator Invention Prioritizer Invention Validator Competitive Intelligence Reports |
Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
|
Talent and Executive Search Services |
Executive search platform using machine learning and NLP to match innovation-driven organisations with commercialisation-ready leadership |
De-risks scaling by aligning technical vision with proven executive capability |
Together, these services form a unified GenAI-enabled platform for innovation triage and commercialisation.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
● Organic Expansion
Scale Invention Intelligence and Recruitment Services through targeted outreach to corporates, VCs, and research institutions.
● Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
● Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
Forward looking statements
Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.
Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".
For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE